Appointment

To: Druwe, Ingrid [Druwe.Ingrid@epa.gov]; drsg-l@indiana.edu
CC: Davis, Allen [Davis.Allen@epa.gov]; Woodall, George [Woodall.George@epa.gov]; Setzer, Woodrow [Setzer.Woodrow@epa.gov]; Flowers, Lynn [Flowers.Lynn@epa.gov]; Beck, Nancy [Beck.Nancy@epa.gov]; Schlosser, Paul [Schlosser.Paul@epa.gov]; Gift, Jeff [Gift.Jeff@epa.gov]; Jarabek, Annie [Jarabek.Annie@epa.gov]; Berner, Ted [Berner.Ted@epa.gov]; Petersen, Dan [Petersen.Dan@epa.gov]; Bussard, David [Bussard.David@epa.gov]; Farrar, David [Farrar.David@epa.gov]; Young, Melanie [Young.Melanie@epa.gov]; Blessinger, Todd [blessinger.todd@epa.gov]; Kopylev, Leonid [Kopylev.Leonid@epa.gov]; Brinkerhoff, Chris [Brinkerhoff.Chris@epa.gov]; Hogan, Karen [Hogan.Karen@epa.gov]; Wright, Michael [Wright.Michael@epa.gov]; Evans, John S. Ex. 6 Personal Privacy (PP) Meghan Lynch [Meghan_Lynch@abtassoc.com]; Zemin Wang Ex. 6 Personal Privacy (PP) James E. Klaunig Ex. 6 Personal Privacy (PP) Haas,Charles Ex. 6 Personal Privacy (PP); Mary Jane Calvey [mjcalvey@rwmsinc.com]; Robby and Brandolyn Thran Ex. 6 Personal Privacy (PP) Ian Collins [Ian.Collins@ghd.com]; Ed Pfau [epfau@hullinc.com]; Rick Reiss [rreiss@exponent.com]; Musso, Michael P. [Michael.Musso@hdrinc.com]; Dalaijamts, Chimeddulam Ex. 6 Personal Privacy (PP) Barbara D. Beck [BBECK@gradientcorp.com]; Lorenz Rhomberg [lrhomberg@gradientcorp.com]; Wout Slob [wout.slob@rivm.nl]; Chiu, Weihsueh Ex. 6 Personal Privacy (PP) Lowney, Carrie A [carrie.a.lowney@zoetis.com]; Arno Swart [arno.swart@rivm.nl]; Gibson, Jacqueline MacDonald Ex. 6 Personal Privacy (PP) Philip Goodrum [pgoodrum@integral-corp.com]; Kenneth Bogen [kbogen@exponent.com]; xly Ex. 6 Personal Privacy (PP); Yeager, Raymond (Phil) [Raymond.Yeager@fda.hhs.gov]; Robinan Gentry [rgentry@ramboll.com]; White, Louise (HC/SC) [louise.white@canada.ca]; Theodore, Shaji [Shaji.Theodore@fda.hhs.gov]; Nance, Patricia (nancepm) [nancepm Ex. 6 Personal Privacy (PP) Simmons, Jane [Simmons.Jane@epa.gov]; Boobis, Alan R [a.boobis@imperial.ac.uk]; Scarano, Louis [Scarano.Louis@epa.gov]; Wayne Landis Ex. 6 Personal Privacy (PP) shays@scipinion.com; Kapraun, Dustin [Kapraun.Dustin@epa.gov]; Therese Manning [therese@enrisks.com.au]; Heidi Reamer [Heidi.Reamer@cardno.com]; Wesselkamper, Scott [Wesselkamper.Scott@epa.gov]; Virunya Bhat [virunyabhat Ex. 6 Personal Privacy (PP) helen.goeden@state.mn.us; Farland,William [William.Farland@ColoState.EDU]; Hearl, Frank J. (CDC/NIOSH/OD) [fjh1@cdc.gov]; ted@TedSimon-Toxicology.com

Subject: [DRSG] Canceled: Monthly DRSG Meeting-CANCELED FOR TODAY 6/5

Start: 6/5/2018 4:00:00 PM
End: 6/5/2018 5:00:00 PM
Show Time As: Free

Importance: High

Recurrence: (none)

Hi DRSG,
We are canceling today's meeting. Below are some updates:

- Weihsueh Chiu, DRSG Pres. Submitted public comment to EPA in regards to proposed EPA rule "Strengthening Transparency in Regulatory Science" as member of the public asking that the reference to DRSG be omitted.
- Resha Putzrath and Sara Henry will be representing DRSG at the SRA Program Meeting on June 26th in Dulles, VA- **Thank you Resha and Sara!**
- Phil Yeager (FDA) submitted the following symposia for SRA 2018 annual meeting:
  Symposium: Evaluating Public Health Impacts of Electronic Nicotine Delivery Systems (Yeager and Weil; FDA) SY16-53k83f (This is the overall symposium number)
  Symposium abstract: Electronic nicotine delivery systems (ENDS) are novel tobacco products that generate a nicotine-containing aerosol inhaled by users. ENDS have been referred to as e-cigarettes, e-hookah, vapes, vaping devices, personal vaporizers, box mods, and trade specific names, among others. ENDS contain flavored and non-flavored liquids, and include a range of device products with different designs, properties, and characteristics that the FDA will evaluate as to whether their marketing in the U.S. is appropriate for the protection of public health. FDA's Center for Tobacco Products will evaluate ENDS submitted in tobacco product applications for scientific data to support these regulatory decisions. A component of this evaluation includes

assessing the impact of ENDS on human health, for both users and nonusers. ENDS products and aerosols contain ingredients, impurities and constituents as byproducts of use, and all may pose a hazard to human health. As ENDS products are inhaled during use, the evaluation of these products considers the relevant adverse human health endpoints from inhalation exposures, whether these are portal-of-entry or systemic effects. This session will provide a discussion of approaches to evaluate adverse health effects from ENDS exposures as applicable to individuals and the population. Topics include presentations about the regulatory authority the FDA has over ENDS; approaches to evaluating ENDS ingredients, particularly nicotine and flavors, and constituents; human exposures to nicotine from ENDS; and vape shop worker exposure to ENDS emissions.

- FDA Tobacco Regulations and Considerations for Evaluating Human Health Risks of Electronic Nicotine Delivery Systems (ENDS) (Weil; FDA) 89-687993
- Evaluating Flavors in Newly Deemed Tobacco Products (Benson; FDA) 88-909247
- Electronic cigarette heterogeneity influences individual and population-level effects (Eissenberg; VCU MCV; Academic) 85-739077
- Evaluation of chemical exposures at three vape shops throughout the United States (Zwack; NIOSH) 87-935636

Phil is requesting $800 from DRSG to cover Dr. Eissenberg's travel costs (would likely need one day registration and flight costs). Approval of the $800 expense is pending discussion by the DRSG officers, which will occur via email.